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irst, some context. My first computer was an Apple IIe. It had a 1.023MHz CPU, 
64KB of RAM and booted off of floppy disks with a whopping 360KB capacity. 
For its time it was amazing; however, there was no such thing as “big data” 
thirty-four years ago. That computer, which I loved so much, would’ve failed misera-
bly if given the task of crunching “big data” numbers. Fast forward to today. My iPh-
one has 128GB and my computer has a terabyte of storage. That terabyte is 8000GB, or 
to put that into context: more than 8000 times the storage capacity of that Apple IIe. In 
short, “big data”—and the machines required to process it—are now a reality.  
The inexorable march of Moore’s Law 
has resulted in changes in all areas of our 
lives, including how we do clinical re-
search. Researchers and patients are 
more connected. We store, access, and 
manipulate data in different ways; we 
conduct studies in multiple countries 
sharing data and samples around the 
world; and cybersecurity and hacking are 
a reality. This article touches on different 
legal aspects arising at the intersection of 
technology, data, and clinical research—
specifically HIPAA (the Health Insurance 
Portability and Accountability Act), hu-
man subjects research, the European data 
law (the General Data Protection Regula-
tion), and data repositories. It attempts to 
explain how two different law-making 
bodies, the US and the EU, have tried to 
balance the necessity of using data for re-
search purposes that benefit society with 
the privacy issues and risks of that same 
data.  
Health Insurance Portability and Ac-
countability Act (HIPAA) and Human 
Subjects Research 
The US has a patchwork of federal 
and state laws that protect different types 
of data. Student records are protected by 
Family Educational Rights and Privacy 
Act (FERPA); financial data by the 
Gramm-Leach-Bliley Act (GLB); health 
data by the Health Insurance Portability 
and Accountability Act of 1996 (HIPAA); 
human subjects research by the Common 
Rule and FDA Regulations; and personal 
information, like driver’s license number 
and social security number, by state law. 
There is no one overarching law that pro-
tects all data. Instead, it is a patchwork of 
laws that sometimes overlap and at other 
times have large holes of information that 
is not covered.1 
The Federal Policy for the Protection 
of Human Subjects, or the Common Rule, 
outlines the basic provisions for Institu-
tional Review Boards (IRBs), informed 
consent, and assurances of compliance. 
F 
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Generally, it applies to research involv-
ing human subjects2 conducted, sup-
ported or otherwise subject to regulation 
by one of eighteen different federal de-
partments or agencies.3 A different set of 
regulations apply to clinical investiga-
tions that are regulated by the Food and 
Drug Administration (FDA) or that sup-
port applications for research or market-
ing permits for products regulated by the 
FDA.4 This includes sponsored trials of 
drugs and devices. Both the Common 
Rule and FDA Regulations require IRBs 
to, where appropriate, verify that there 
are adequate provisions in place to pro-
tect the privacy of subjects and to main-
tain the confidentiality of data.5 The 
Common Rule requires that the informed 
consent form contain a statement describ-
ing the extent, if any, to which the confi-
dentiality of records identifying the sub-
ject will be maintained.6 
The Common Rule does not apply to 
public records or records in which the re-
search subject cannot be identified di-
rectly or indirectly linked to the research 
subject.7 So, if the information cannot be 
linked back to the subject, under the 
Common Rule it does not constitute hu-
man subjects research.8 However, under 
the FDA regulations it may still be con-
sidered a clinical investigation.  
HIPAA applies a much different 
standard than the Common Rule and 
FDA Regulations. HIPAA applies to 
“covered entities,” which are defined as 
health care providers that transmit any 
information in an electronic form in asso-
ciation with standard transactions, health 
plans, and health care clearing houses.9  It 
does not apply to all researchers; it ap-
plies to researchers that are covered enti-
ties and may apply, depending on the sit-
uation, to researchers who work for cov-
ered entities or obtain their data from a 
covered entity.10 For instance, if a data re-
pository is created by an academic medi-
cal center or health system, then HIPAA 
likely applies. However, if a group of in-
dividuals or a disease foundation create a 
data repository by submitting their own 
data, HIPAA likely does not apply.  
Many researchers believe if they re-
move the patient’s name and social secu-
rity number they have de-identified data 
under HIPAA. These researchers would 
be incorrect. For information to be con-
sidered de-identified it has to meet the re-
quirements of either the safe harbor or ex-
pert determination. The safe harbor re-
quires removal of the following identifi-
ers of the patient and the patient’s rela-
tives, employers, or household members: 
• Names;
• All geographic subdivisions
smaller than a state, including
street address, city, county, pre-
cinct, ZIP code, and their equiva-
lent geocodes, except for the ini-
tial three digits of the ZIP code if,
according to the current publicly
available data from the Bureau of
the Census:
o The geographic unit
formed by combining all
ZIP codes with the same
three initial digits contains
more than 20,000 people;
and
o The initial three digits of a
ZIP code for all such geo-
graphic units containing
20,000 or fewer people is
changed to 000;
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• All elements of dates (except
year) for dates that are directly re-
lated to an individual, including
birth date, admission date, dis-
charge date, death date, and all
ages over 89 and all elements of
dates (including year) indicative
of such age, except that such ages
and elements may be aggregated
into a single category of age 90 or
older;
• Telephone numbers;
• Vehicle identifiers and serial
numbers, including license plate
numbers;
• Fax numbers;
• Device identifiers and serial num-
bers;
• Email addresses;
• Web Universal Resource Locators
(URLs);
• Social security numbers;
• Internet Protocol (IP) addresses;
• Medical record numbers;
• Biometric identifiers, including
finger and voice prints;
• Health plan beneficiary numbers;
• Full-face photographs and any
comparable images;
• Account numbers;
• Any other unique identifying
number, characteristic, or code;
and
• Certificate/license numbers.11
To fit within the safe harbor method
all the identifiers above have to be re-
moved, encoded, or randomized; no ex-
ceptions.12 In addition, the researcher 
cannot have actual knowledge that the in-
formation could be used alone or in com-
bination with other information to iden-
tify an individual who is a subject of the 
information.13 It is important to note that 
the safe harbor method does not require 
removal of the physician or other health 
care provider’s information, but only the 
patient’s and family members’ infor-
mation. 
Another option is the expert determi-
nation method. Under this method, a 
qualified statistician determines that the 
risk is very small that the information 
could be used alone or in combination 
with other reasonably available infor-
mation by an anticipated recipient to re-
identify an individual. In addition, the 
expert must document the methods and 
analysis that support this decision. 14 This 
method could allow certain identifiers to 
remain that would otherwise have to be 
removed under the safe harbor method of 
compliance.  
If the data is de-identified under ei-
ther the safe harbor or expert determina-
tion method, then HIPAA and its associ-
ated regulations do not apply to that 
data, and there are no limitations under 
HIPAA on its use or disclosure. For ex-
ample, you may sell de-identified data 
(unless it is subject to a DUA or other 
agreement that prohibits it).  
Researchers often need information 
that is not available in properly de-iden-
tified data sets. The most common re-
quest is for dates—often birth, death, ad-
mission, and discharge. In this instance, a 
researcher would use a limited data set 
(LDS), instead of fully identified infor-
mation. A LDS is information from which 
the following identifiers of the individual 
or his or her relatives, employers or 
household members are removed: 
• names;
• street addresses (other than town,
city, state and zip code); 
• telephone numbers;
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• fax numbers;
• e-mail addresses;
• Social Security numbers;
• medical records numbers;
• health plan beneficiary numbers;
• account numbers;
• certificate license numbers;
• vehicle identifiers and serial num-
bers, including license plates;
• device identifiers and serial num-
bers;
• URLs;
• IP address numbers;
• biometric identifiers (including
finger and voice prints); and
• full face photos (or comparable
images).15
Examples of information that may re-
main and still be a LDS include: 
• dates such as admission, dis-
charge, service, birth, and death;
• city, state, five digit or more zip
code; and
• ages in years, months, days, or
hours.
An LDS is still considered protected 
health information even though there are 
fewer identifiers and less risk than fully 
identified protected health information.16 
The HIPPA Privacy Regulations require 
covered entities enter into a data use 
agreement with any recipient of a LDS. 
These agreements must include the fol-
lowing: 
• a description of the permitted
uses and disclosures of the lim-
ited data set;
• a list of who may use or receive
the information;
• a requirement that the recipient
will not use or further disclose the
information, except as permitted
by the agreement or as permitted
by law;
• a requirement that the recipient
use appropriate safeguards to
prevent a use or disclosure that is
not permitted by the agreement;
• a requirement that the recipient
report to the covered entity any
unauthorized use or disclosure of
which it becomes aware;
• a requirement that the recipient
ensure that any agents (including
a subcontractor) to whom it pro-
vides the information will agree
to the same restrictions as pro-
vided in the agreement; and
• a statement that the recipient will
not re-identify the information or
contact the individuals.17
A data use agreement has become a 
standardized agreement which is usually 
not a difficult agreement to negotiate. In-
creasingly, data use agreements are also 
being used for the disclosure of de-iden-
tified data, to prohibit the selling, re-dis-
closure, and noncompetitive use of de-
identified data by the recipient. 
Data Repositories 
Creation of a Data Repository 
A data repository is a collection or 
warehouse of data.18 It can contain de-
identified data, a limited data set, or fully 
identifiable information. There are two 
separate legal analyses that must occur 
when creating a data repository: first, 
does HIPAA apply; and second, is it con-
sidered human subject research under 
the Common Rule.  
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The HIPAA analysis starts with a 
seemingly simple concept: the use or dis-
closure of protected health information 
by a covered entity for research purposes 
requires that certain conditions under the 
HIPAA Privacy Rule be met. There is a lot 
of information packed in that one sen-
tence. HIPAA applies to covered entities. 
So, if the researcher is not a covered en-
tity, is not employed by a covered entity, 
and does not obtain the information from 
a covered entity then HIPAA and its as-
sociated regulations do not apply. Also, it 
only applies to protected health infor-
mation. If the information is de-identified 
according to the HIPAA Privacy Rule (ei-
ther by the safe harbor or expert determi-
nation method) then HIPAA no longer 
applies to the de-identified data. Finally, 
it must be for a research purpose. Re-
search is defined as a “systematic investi-
gation, including research development, 
testing, and evaluation, designed to de-
velop or contribute to generalizable 
knowledge.”19 If the use or disclosure is 
for health care operations of the covered 
entity then patient authorization is not re-
quired. Health care operations include 
conducting quality assessment and im-
provement activities, including outcomes 
evaluation and development of clinical 
guidelines, provided that obtaining gen-
eralizable knowledge is not the primary 
purpose; patient safety activities; and 
population-based activities relating to 
improving health or reducing health 
care costs, protocol development, case 
management and care coordination, and 
contacting of health care providers and 
patients with information about treat-
ment alternatives.20 Therefore, organiza-
tions could create a data repository for 
quality improvement activities without 
obtaining patient authorization or a 
waiver of authorization.  
If a covered entity uses or discloses 
protected health information to create a 
database to conduct research, then the 
creation of the database itself is a research 
activity that must meet the requirements 
of the HIPAA Privacy Rule. If the data re-
pository is created from a limited data set 
then one option is to use a data use agree-
ment, which would enable the subse-
quent accessing of the data for research 
purposes to be achieved through a simi-
lar data use agreement.21 Another option 
for creating the research repository is to 
obtain a HIPAA compliant authorization 
of each person’s data that is contained in 
the repository. This may be a viable op-
tion for a small local database that is start-
ing from scratch, but it is unlikely to work 
for anything but the smallest data reposi-
tory. The more likely option is a waiver of 
the authorization requirement.  
To create the research repository 
without obtaining each person’s signed 
authorization, the researcher must get a 
written waiver of the authorization re-
quirement from either an IRB or a privacy 
board that meets the Privacy Rule re-
quirements.22 The covered entity—prior 
to the use or disclosure—would obtain 
documentation of the following: 
• Identification of the IRB or Pri-
vacy Board and the date on which
the alteration or waiver of author-
ization was approved;
• A statement that the IRB or Pri-
vacy Board has determined that
the alteration or waiver of author-
ization, in whole or in part, satis-
fies the three criteria in the Pri-
vacy Rule (listed below);
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• A brief description of the pro-
tected health information for
which use or access has been de-
termined to be necessary by the
IRB or Privacy Board;
• A statement that the alteration or
waiver of authorization has been
reviewed and approved under ei-
ther normal or expedited review
procedures; and
• The signature of the chair or other
member, as designated by the
chair, of the IRB or the Privacy
Board, as applicable.23
The following three criteria must be 
satisfied for an IRB or Privacy Board to 
approve a waiver of authorization under 
the Privacy Rule: 
• The use or disclosure of protected
health information involves no
more than a minimal risk to the
privacy of individuals, based on,
at least, the presence of the fol-
lowing elements:
o an adequate plan to pro-
tect the identifiers from
improper use and disclo-
sure;
o an adequate plan to de-
stroy the identifiers at the
earliest opportunity con-
sistent with conduct of the
research, unless there is a
health or research justifi-
cation for retaining the
identifiers or such reten-
tion is otherwise required
by law; and
o adequate written assur-
ances that the protected
health information will
not be reused or disclosed
to any other person or en-
tity, except as required by 
law, for authorized over-
sight of the research pro-
ject, or for other research 
for which the use or dis-
closure of protected health 
information would be per-
mitted by this subpart; 
• The research could not practica-
bly be conducted without the
waiver or alteration; and
• The research could not practica-
bly be conducted without access
to and use of the protected health
information.24
At the same time as the waiver of au-
thorization under HIPAA is being ob-
tained, the IRB is also determining 
whether or not it considers the data re-
pository to be “human subjects research” 
covered under the Common Rule.25 The 
Common Rule does not apply if both of 
the following conditions are met: the data 
was not collected specifically for the cur-
rently proposed research project through 
an interaction or intervention with living 
individuals, and the investigator(s) can-
not readily ascertain the identity of the in-
dividual(s) to whom the coded private in-
formation pertains. 26 Conversely, obtain-
ing identifiable private information for 
research purposes constitutes human 
subjects research. 27 
If the IRB determines that the Com-
mon Rule applies, then: (1) either the re-
searcher will get consent from each re-
search subject; or (2) in addition to the 
HIPAA waiver of authorization, the re-
searcher will also request waiver of in-
formed consent under the Common Rule. 
To approve a waiver of the requirement 
to obtain informed consent or approve a 
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consent procedure which does not in-
clude, or which alters, some or all of the 
elements of informed consent require-
ments the IRB must determine and docu-
ment the following:  
• the research involves no more
than minimal risk to the subjects;
• the waiver or alteration will not
adversely affect the rights and
welfare of the subjects;
• the research could not practicably
be carried out without the waiver
or alteration; and
• whenever appropriate, the sub-
jects will be provided with addi-
tional pertinent information after
participation. 28
Several changes to the Common Rule 
go into effect July 19, 2018 that impact the 
informed consent process.29  These re-
visions add a provision for secondary re-
search uses of identifiable private infor-
mation and identifiable biospecimens; 30 
add a provision for broad consent for the 
storage, maintenance and secondary re-
search use of identifiable private infor-
mation and identifiable biospecimens; 31 
modify the list of required elements of in-
formed consent to include an additional 
statement if private identifiable infor-
mation or identifiable biospecimens are 
collected32 and additional language for 
the consent form if biospecimens (even if 
identifiers are removed) will be used for 
commercial profit33  or if research of bio-
specimens will or might include whole 
genome sequencing; 34 and a provision 
approving research where a researcher 
obtains information or biospecimens 
without consent for the purpose of 
screening, recruiting, or determining eli-
gibility of a prospective research subject 
if certain conditions are met. 35  
Once all of the approvals are ob-
tained, the data repository may be popu-
lated with data. However, if new data 
sources are added, data elements col-
lected are changed, or the protocol is re-
vised, then the researcher would have to 
do the HIPAA analysis again. For in-
stance, if the repository was originally 
considered to be de-identified or a lim-
ited data set, is that still the case after ad-
ditional data is added? Also the IRB 
would want to review any modifications 
to the data repository or associated pro-
tocol prior to their implementation.  
Accessing Data in a Data Repository 
Each time protected health infor-
mation (even a limited data set) is ac-
cessed for a research purpose, then the re-
quirements for access must be met as 
well. Like the creation of a data reposi-
tory, this is potentially a two-part analy-
sis. The first part is the analysis under 
HIPAA; the second, an analysis under the 
Common Rule.  
Under HIPAA, to access de-identified 
data no additional steps are required un-
less as part of the protocol that created 
the data repository the researcher stated 
that a data access or system access agree-
ment would be signed by researchers ac-
cessing the data. In this case, the protocol 
must be followed. If a limited data set or 
fully identifiable protected health infor-
mation is requested, then under the 
HIPAA Privacy Rule one of the following 
circumstances and conditions must be 
met: 
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• The request is a review prepara-
tory to research and certain repre-
sentations are obtained from the
researcher;
• The research is solely on dece-
dents’ information and certain
representations are obtained from
the researcher;
• A HIPAA-compliant authoriza-
tion was signed by each subject of
the PHI, granting specific written
permission for the access and use
of the information;
• An IRB or Privacy Board has
granted and documented the
grant of a waiver or an alteration
of the authorization requirement
(if an alteration of the authoriza-
tion is granted, a signed authori-
zation is required from each indi-
vidual);
• The PHI has been de-identified in
accordance with the standards set
by the Privacy Rule (in which
case, the information is no longer
PHI);
• The information is released in the
form of a limited data set and a
data use agreement between the
researcher and the covered entity
is signed;
• Informed consent of the individ-
ual to participate in the research,
an IRB waiver of such informed
consent, or other express legal
permission to use or disclose the
information for the research is
grandfathered by the transition
provisions. 36
The Common Rule analysis is just as 
complicated as the HIPAA analysis, 
maybe even more so. Under the Common 
Rule, obtaining identifiable private infor-
mation for research purposes constitutes 
human subjects research. This includes 
information that is already in the posses-
sion of the investigator. 37 Conversely, re-
search is not considered human subject 
research if the research only involves 
coded private information of human sub-
jects if both of the following conditions 
are met: (1) the private information was 
not collected specifically for the proposed 
research project through an interaction or 
intervention with living individuals; and 
(2) the investigator(s) cannot readily as-
certain the identity of the individual(s) to
whom the coded private information per-
tains. 38
Information is considered identifiable 
when the information can be linked to 
specific individuals by the investigator(s) 
either directly or indirectly through cod-
ing systems. Additionally, an investiga-
tor is broadly defined to include anyone 
involved in conducting the research. 39 An 
investigator would not include an honest 
broker who solely provides de-identified 
or coded information as long as the hon-
est broker does not collaborate on other 
activities related to the conduct of this re-
search with the investigator(s) who re-
ceive(s) such information.40 An example 
of the difference between these two sce-
narios in plain English is: First, a re-
searcher accesses a database with patient 
information that identifies the patient, 
queries the information, and records the 
results in a way that is coded but main-
tains the key to decode the data. Or, sec-
ond, an honest broker, who is not part of 
the research team, accesses the database, 
queries the data, codes the results so that 
the patients are not identifiable, and the 
honest broker maintains the linking code. 
KU MASC 2017 Research Retreat 54
The first example is human subjects re-
search, while the second is not.  
Even if the accessing of data is consid-
ered human subjects research, it may be 
exempt under the Common Rule. Ac-
cording to the guidance published by the 
Office for Human Subjects Protections, 
the most relevant exemption is if the in-
formation obtained by the investigator is 
recorded in such a manner that the indi-
viduals cannot be identified directly or 
indirectly through identifiers linked to 
the individuals.41 Using our previous ex-
amples, the researcher would access a da-
tabase with patient information that iden-
tifies the patient, would query the infor-
mation, and would record the results in a 
way that is coded with no way to decode 
the data to identify the individuals.  
If the access to the research repository 
is considered human subjects research 
that is not exempt, then the investigator 
must submit a study submission as a new 
study or a modification to an existing 
study. In addition, the researcher is likely 
to request a waiver of the informed con-
sent requirement as well. 
The European Union and the Gen-
eral Data Protection Regulation 
This final section is provided for illus-
trative purposes in order to highlight 
some of the issues that may arise when 
US researchers want to use data from 
other countries for their research. I have 
used the EU as an example. As this article 
has shown, the US has a complex maze of 
laws with limitations and exceptions 
which often makes researchers and their 
attorneys want to scream in frustration. 
The EU data protection laws are just as 
complex, but unlike the US, the EU has a 
single data protection regime that applies 
to all data. The previous law was the Data 
Protection Directive, 42 which is being re-
placed (effective May 25, 2018) by the 
General Data Protection Regulation 
(GDPR).43 Like HIPAA, the GDPR has 
sanctions44 and special rules for personal 
data breaches. 45 Unlike HIPAA, it also in-
cludes a right to be forgotten, or erasure, 46 
and there are provisions for the portabil-
ity of data. 47  
The GDPR was designed to harmo-
nize the different data privacy laws 
across Europe, give all EU citizens con-
trol of how their data is used and pro-
tected, and to reshape the way organiza-
tions across the region approach data pri-
vacy. It is intended to reach beyond the 
territory of the EU to individuals and 
businesses that offer goods and services 
to or monitor the behavior of individuals 
in the EU. 48 This impacts US researchers 
because US researchers are increasingly 
wanting to use EU and other countries’ 
data and are thus dragged into the quag-
mire that is international data protection 
law. This section provides an overview of 
the GDPR. What remains to be seen is 
what impact the GDPR will have on data 
repositories, big data research, and per-
sonal data in “the cloud” as it evolves 
over time, especially with the large po-
tential sanctions. Since the GDPR is not 
yet in effect, it has yet to be interpreted by 
courts, researchers, and lawmakers 
throughout Europe.  
The GDPR applies to “personal data,” 
which is defines as: 
[A]ny information
relating to an identi-
fied or identifiable
natural person
(“data subject”); an
identifiable natural
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person is one who 
can be identified, di-
rectly or indirectly, 
in particular by ref-
erence to an identi-
fier such as a name, 
an identification 
number, location 
data, an online iden-
tifier or to one or 
more factors specific 
to the physical, 
physiological, ge-
netic, mental, eco-
nomic, cultural or 
social identity of that 
natural person. 49 
This broad definition is likely a moving 
target. An identifiable person defined as 
someone who can be identified indirectly 
will change over time as more infor-
mation becomes publicly available and as 
technology changes.50 
Under the GDPR there is not a “de-
identified data” safe harbor or expert de-
termination, but instead data can be 
anonymized and pseudonymised. When 
data is anonymized, it is no longer per-
sonal data because the individual cannot 
be identified either directly or indi-
rectly.51 Pseudonymisation is defined by 
the GDPR as processing personal data in 
such a way that the data can no longer be 
attributed to a specific data subject with-
out the use of additional information. The 
GDPR not only requires the “additional 
information” be stored separately, but 
also requires various technical and or-
ganizational measures to ensure that the 
personal data cannot be attributed to an 
identified or identifiable natural person.52 
An example of pseudonymisation is en-
cryption, which renders the original data 
unintelligible and the process cannot be 
reversed without access to the correct de-
cryption key. The GDPR requires that 
this additional information (the decryp-
tion key) be kept separately from the 
pseudonymised data. Although the 
GDPR encourages the use of pseudony-
misation to reduce risks to the data sub-
jects, pseudonymised data is still consid-
ered personal data and, therefore, re-
mains covered by the GDPR. 53 
The GDPR also recognizes special cat-
egories of personal data which are con-
sidered to be particularly sensitive. The 
processing (or use) of data related to 
these special categories is generally pro-
hibited by the GDPR: 
Processing of personal 
data revealing racial or 
ethnic origin, political 
opinions, religious or phil-
osophical beliefs, or trade 
union membership, and 
the processing of genetic 
data, biometric data for 
the purpose of uniquely 
identifying a natural per-
son, data concerning 
health or data concerning 
a natural person’s sex life 
or sexual orientation shall 
be prohibited.” 54 
There are two exceptions to this pro-
hibition that are likely to apply to re-
search involving the special categories of 
data, which includes health data or pro-
tected health information under HIPAA. 
The first exception requires the data sub-
ject give explicit consent to the processing 
of the personal data for one or more spec-
ified purposes. 55 The GDPR defines con-
sent of the data subject as “any freely 
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given, specific, informed and unambigu-
ous indication of the data subject’s wishes 
by which he or she, by a statement or by 
a clear affirmative action, signifies agree-
ment to the processing of personal data 
relating to him or her.” 56 If the consent is 
provided in a document that concerns 
other matters, the request for consent 
must be presented in a way that is clearly 
distinguishable from the other matters, in 
an intelligible and easily accessible form, 
and using clear and plain language. 57 In 
addition, consent should not be consid-
ered freely given if the data subject had 
no genuine or free choice or is unable to 
refuse or withdraw consent without pen-
alty.58 However, the GDPR also recog-
nizes that it is often not possible to fully 
identify the purpose of personal data pro-
cessing for research purposes at the time 
of data collection; therefore, data subjects 
should be allowed to provide their con-
sent to certain areas of research or parts 
of research projects when in keeping with 
recognized ethical standards for scientific 
research.59 If a researcher wants to reuse 
the data for research (e.g., secondary re-
search) and does not have explicit con-
sent for the secondary use, then the re-
searcher would decide if the use was 
comparable to the previously consented 
use. The “compatibility test” looks at the 
following factors: 
• any link between the purpose(s)
for which the personal data was
collected and the purpose(s) of
the intended use;
• the context in which the personal
data was collected, in particular
the relationship between data
subjects and the controller;
• the nature of the personal data, in
particular are there special cate-
gories of personal data or per-
sonal data related to criminal con-
victions and offences;
• the possible consequences of the
intended further processing for
data subjects; and
• whether there are appropriate
safeguards. 60
The second exception is for research 
purposes that meet the requirements for 
applicable safeguards outlined in Article 
89(1)61 and based on EU or an EU coun-
try’s law that is proportionate to the re-
search aim pursued, respect the right to 
data protection, and provide for suitable 
and significant measures to safeguard the 
fundamental rights and interests of the 
data subject.62 
 For consent to be “waived” the re-
search should have adequate safeguards 
in place to protect the data subject’s infor-
mation and have a valid research pur-
pose. For secondary research the second-
ary use must meet the requirements for 
applicable safeguards outlined in Article 
89(1) and be compatible with the initial 
purpose for collecting the data (“pur-
poses limitation”).63 If personal data has 
not been provided by the data subject 
(e.g., secondary research), then unless the 
exception for research is met, the data 
subject should be provided with the fol-
lowing: the identity and the contact de-
tails of the controller and where applica-
ble the data protection officer and the 
controller's representative; the purposes 
for processing the data and the legal basis 
for the processing; the categories of per-
sonal data concerned; the data recipients 
or categories of data recipients; and 
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where applicable, that the controller in-
tends to transfer personal data to a recip-
ient in a third country or international or-
ganization, whether there is an adequacy 
decision by the Commission, or if the 
transfer is made subject to appropriate 
safeguards.64 The research exception for 
this requirement is if the provision of the 
information would be impossible or in-
volve a disproportionate effort and likely 
render impossible or seriously impair the 
research. Then, subject to the conditions 
and safeguards referred to in Article 
89(1), the researcher must take appropri-
ate measures to protect the data subject's 
rights and freedoms and legitimate inter-
ests, including making the information 
publicly available.65 
Conclusion 
Research and technology are moving 
forward at an incredible pace. Technol-
ogy has enabled researchers to store, ma-
nipulate and calculate data in new ways, 
which has created benefits and risks for 
researchers and data subjects. The US has 
a patchwork of laws to address the use of 
data in clinical research and data reposi-
tories, but there are some gaps. Further, 
as the world of research has gotten 
smaller and data is shared around the 
globe, “big data” and research has never 
been more complicated. US laws like 
HIPAA and the Common Rule comple-
ment and contradict other laws like the 
EU GDPR. So, researchers who use data 
from multiple countries must navigate 
not only their own country’s laws but 
also international legal waters often with-
out a clear path. 
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